Navigation Links
Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
Date:1/18/2011

SAN DIEGO, Jan. 18, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced the launch of OFIRMEV™ (acetaminophen) injection, the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States.  The U.S. Food and Drug Administration (FDA) approved OFIRMEV in November 2010 for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.  OFIRMEV is now available to hospitals across the U.S.  

"With the launch of OFIRMEV, physicians will have access to the first new class of IV pain medication in nearly two decades," said Ted Schroeder, president and CEO of Cadence.  "Our focus now turns to working closely with hospitals and physicians to expand access and utilization and establish OFIRMEV as a foundational therapy in the management of pain in hospitalized patients.  At this initial stage of commercialization, we are pleased with the early signals of physician demand and formulary access.  We anticipate that by the end of this year OFIRMEV will be on formulary at approximately 800 - 1,000 hospitals, which will represent approximately half of the IV analgesic opportunity."

The national launch of OFIRMEV is being supported by 147 hospital sales specialists and 13 field medical science liaisons.  These field personnel have extensive hospital experience and have completed rigorous training in preparation for the launch.  Through agreements with the three major pharmaceutical wholesalers, distribution centers across the U.S. are fully stocked and accepting orders from hospitals.  

Until now, the only injectable drugs available to treat pain and fever were opioids and NSAIDs.  When used as part of a multi-modal approach to pain management in placebo-controlled clinical stu
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
3. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
4. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
6. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
7. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... ... The 2015 Market Research Report on the Global Propanol Industry is ... with a focus on the Chinese situation. Major companies included in the propanol market ... Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report provides a ...
(Date:7/30/2015)... , July 30, 2015   Aratana Therapeutics, ... therapeutics company focused on the licensing, development and ... today announced that its strategic partner VetStem Biopharma, ... confirmation study of AT-016, an adipose-derived allogeneic stem ... treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/30/2015)... New York, NY (PRWEB) , ... July 30, 2015 , ... As part of its ... raw material and technical service business units, Whitehouse Laboratories is pleased ... facility will be adjacent to the Container Center of Excellence and will be strictly dedicated ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... guards came to the DHS Science and Technology Directorates ... was an emergency escape hood worthy of James Bond: a ... folding to the dimensions of a DVD case, and donnable ... be maintenance-free, filter nerve, blood, and blister agents, remove toxic ...
... Today at 5:00 p.m., CAMBRIDGE, Mass., April 21 ... the FDA has informed the,company of its opinion that ... Myozyme produced at the 2000L scale should be,classified as ... of the molecules. Currently, Genzyme has U.S.,approval to sell ...
... Antacid Delivers Faster Relief, ... Increased Convenience and Great Taste, PITTSBURGH, April 21 ... campaign,for the new TUMS(R) QuikPak(TM), the first and only instant ... part of,a larger new "Bring It On" brand strategy designed ...
Cached Biology Technology:Boys in the Hood 2Genzyme Provides Update on Myozyme(R) Manufacturing 2Genzyme Provides Update on Myozyme(R) Manufacturing 3Genzyme Provides Update on Myozyme(R) Manufacturing 4Genzyme Provides Update on Myozyme(R) Manufacturing 5New TUMS(R) QuikPak(TM) Campaign Offers Innovative Heartburn Relief with a Little Help from the Jetsons 2
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Huawei has selected ... solution for its stylish smartwatch. Huawei chose the ... reliability, low power and highly responsive human interface ... Huawei designers also required a classic round watch ...
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, featuring FPC,s ... in 2015 that relate to sales of FPC1025 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... China and we are proud that ... Axon , its first smartphone ...
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... season almost upon us and increasing concerns about ... pickups, it is timely that researchers should turn ... Writing in a forthcoming issue of the Inderscience ... Management, researchers suggest a new approach to cutting ...
... the Commission for Environmental Cooperation (CEC) reveals that a ... environment15 percent for the United States and Canada from ... industrial facilities that are the largest generators of emissions. ... leading role of the largest waste-producing facilities stands in ...
... State University and the University of Bucharest, Romania, ... dobrogea in eastern Romania. Previously unexamined, these ancient ... 150 million years ago during the Jurassic period. ... determine various aspects of biodiversity and patterns of ...
Cached Biology News:Computer solution to delivery problem 2Toxic releases down from North American industry leaders, increasing from other facilities 2
... APAgene kits are designed to rapidly ... using our patented APA Technology. ... at an extraordinarily competitive price. All ... kit. The Locator Kit can be ...
Rabbit polyclonal to Yaf9 ( Abpromise for all tested applications)....
Bovine Calf Serum...
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
Biology Products: